These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 24484431)

  • 1. Next-generation DES: the COMBO dual therapy stent with Genous endothelial progenitor capturing technology and an abluminal sirolimus matrix.
    Woudstra P; de Winter RJ; Beijk MA
    Expert Rev Med Devices; 2014 Mar; 11(2):121-35. PubMed ID: 24484431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The REMEDEE trial: a randomized comparison of a combination sirolimus-eluting endothelial progenitor cell capture stent with a paclitaxel-eluting stent.
    Haude M; Lee SW; Worthley SG; Silber S; Verheye S; Erbs S; Rosli MA; Botelho R; Meredith I; Sim KH; Stella PR; Tan HC; Whitbourn R; Thambar S; Abizaid A; Koh TH; Den Heijer P; Parise H; Cristea E; Maehara A; Mehran R
    JACC Cardiovasc Interv; 2013 Apr; 6(4):334-43. PubMed ID: 23523459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a novel prohealing stent designed to deliver sirolimus from a biodegradable abluminal matrix.
    Granada JF; Inami S; Aboodi MS; Tellez A; Milewski K; Wallace-Bradley D; Parker S; Rowland S; Nakazawa G; Vorpahl M; Kolodgie FD; Kaluza GL; Leon MB; Virmani R
    Circ Cardiovasc Interv; 2010 Jun; 3(3):257-66. PubMed ID: 20442358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective randomised study using optical coherence tomography to assess endothelial coverage and neointimal proliferation at 6-months after implantation of a coronary everolimus-eluting stent compared with a bare metal stent postdilated with a paclitaxel-eluting balloon (OCTOPUS Trial): rationale, design and methods.
    Poerner TC; Otto S; Gassdorf J; Janiak F; Danzer C; Ferrari M; Figulla HR
    EuroIntervention; 2011 May; 7 Suppl K():K93-9. PubMed ID: 22027737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genous endothelial progenitor cell-capturing stent system: a novel stent technology.
    Klomp M; Beijk MA; de Winter RJ
    Expert Rev Med Devices; 2009 Jul; 6(4):365-75. PubMed ID: 19572791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current evidence for the safety and efficacy of the bio-engineered dual therapy COMBO stent.
    Kalkman DN; Chandrasekhar J; de Winter RJ; Mehran R
    Minerva Cardioangiol; 2018 Jun; 66(3):262-272. PubMed ID: 29381028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endothelial progenitor cell capture stent: safety and effectiveness.
    Sethi R; Lee CH
    J Interv Cardiol; 2012 Oct; 25(5):493-500. PubMed ID: 22612275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale and study design of the OISTER trial: optical coherence tomography evaluation of stent struts re-endothelialization in patients with non-ST-elevation acute coronary syndromes--a comparison of the intrEpide tRapidil eluting stent vs. taxus drug-eluting stent implantation.
    Iaccarino D; Politi L; Rossi R; Sgura F; Monopoli D; Modena MG; Sangiorgi GM
    J Cardiovasc Med (Hagerstown); 2010 Jul; 11(7):536-43. PubMed ID: 20090547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Are impaired endothelial progenitor cells involved in the processes of late in-stent thrombosis and re-endothelialization of drug-eluting stents?
    Zhao FH; Chen YD; Jin ZN; Lu SZ
    Med Hypotheses; 2008; 70(3):512-4. PubMed ID: 17764856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel polymer-free paclitaxel-eluting stent with a nanoporous surface for rapid endothelialization and inhibition of intimal hyperplasia: Comparison with a polymer-based sirolimus-eluting stent and bare metal stent in a porcine model.
    Jia H; Liu H; Kong J; Hou J; Wu J; Zhang M; Tian J; Liu H; Ma L; Hu S; Huang X; Zhang S; Zhang S; Yu B; Jang IK
    J Biomed Mater Res A; 2011 Sep; 98(4):629-37. PubMed ID: 21732525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel "pro-healing" approach: the COMBO™ dual therapy stent from a pathological view.
    Zarpak R; Sanchez OD; Joner M; Guy LG; Leclerc G; Virmani R
    Minerva Cardioangiol; 2015 Feb; 63(1):31-43. PubMed ID: 25502187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug-eluting stents.
    García-García HM; Vaina S; Tsuchida K; Serruys PW
    Arch Cardiol Mex; 2006; 76(3):297-319. PubMed ID: 17091802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent.
    Doostzadeh J; Clark LN; Bezenek S; Pierson W; Sood PR; Sudhir K
    Coron Artery Dis; 2010 Jan; 21(1):46-56. PubMed ID: 19952925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two-year follow-up of the Genous™ endothelial progenitor cell capturing stent versus the Taxus Liberté stent in patients with de novo coronary artery lesions with a high-risk of restenosis: a randomized, single-center, pilot study.
    Beijk MA; Klomp M; van Geloven N; Koch KT; Henriques JP; Baan J; Vis MM; Tijssen JG; Piek JJ; de Winter RJ
    Catheter Cardiovasc Interv; 2011 Aug; 78(2):189-95. PubMed ID: 21542109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).
    Ormiston J; Webster M; Stewart J; Vrolix M; Whitbourn R; Donohoe D; Knape C; Lansky A; Attizzani GF; Fitzgerald P; Kandzari DE; Wijns W
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1026-34. PubMed ID: 24055443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Genous™ endothelial progenitor cell capture stent accelerates stent re-endothelialization but does not affect intimal hyperplasia in porcine coronary arteries.
    van Beusekom HM; Ertaş G; Sorop O; Serruys PW; van der Giessen WJ
    Catheter Cardiovasc Interv; 2012 Feb; 79(2):231-42. PubMed ID: 21834062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real polymer-free sirolimus- and probucol-eluting versus biodegradable polymer sirolimus-eluting stents for obstructive coronary artery disease: DKPLUS-Wave 1, a multicenter, randomized, prospective trial.
    Chen SL; Ye F; Zhang JJ; Zou JJ; Qian XS; Li F; Yang S; Ge Z; Shan SJ; Li XB; Xu T; Kan J; Lin L; Han YL
    Cardiovasc Ther; 2013 Aug; 31(4):193-200. PubMed ID: 22954234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative healing response after sirolimus- and paclitaxel-eluting stent implantation in a pig model of restenosis.
    Silva GV; Fernandes MR; Madonna R; Clubb F; Oliveira E; Jimenez-Quevedo P; Branco R; Lopez J; Angeli FS; Sanz-Ruiz R; Vaughn WK; Zheng Y; Baimbridge F; Canales J; Cardoso CO; Assad JA; Falotico R; Perin EC
    Catheter Cardiovasc Interv; 2009 May; 73(6):801-8. PubMed ID: 19309735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experimental assessment of effects of antiproliferative drugs of drug-eluting stents on endothelial cells.
    Miura K; Nakaya H; Kobayashi Y
    Cardiovasc Revasc Med; 2015 Sep; 16(6):344-7. PubMed ID: 26253188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paclitaxel and sirolimus differentially affect growth and motility of endothelial progenitor cells and coronary artery smooth muscle cells.
    Clever YP; Cremers B; Krauss B; Böhm M; Speck U; Laufs U; Scheller B
    EuroIntervention; 2011 May; 7 Suppl K():K32-42. PubMed ID: 22027725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.